University of Virginia Library

Search this document 

 
expand section
 
 
CONFLICT OF INTEREST EXEMPTION: GENEURON THERAPEUTICS, INC.
 
 
 
 
 
 
 
 
 
 
expand section
 
 
 
expand section
expand section
 
 
expand section
expand section

CONFLICT OF INTEREST EXEMPTION: GENEURON THERAPEUTICS, INC.

The following resolution was adopted:

WHEREAS, the School of Medicine wishes to enter into sponsored research contracts with GeNeuron, Inc., for developing biologically enhanced devices for treatment of neurovascular disease; and

WHEREAS, Gerald R. Hankins, Ph.D., Gregory A. Helm, M.D., David F. Kallmes, M.D., have disclosed in advance their equity interests of 23.3, 24.2, 23.8, percent, respectively, in GeNeuron Therapeutics, Inc., and

WHEREAS, the University's entry into research agreements with GeNeuron Therapeutics, Inc., would thereby expose Mr. Hankins, Dr. Helm, and Dr. Kallmes to violation of the Virginia Conflicts of Interest Act unless approved by the Board as permitted by §2.1-639.6(c) (7) of the Code of Virginia;

RESOLVED that the conflict of interest of Gerald R. Hankins, Ph.D., Gregory A. Helm, M.D., and David F. Kallmes, M.D., is approved by the Board of Visitors in order to permit the University to enter into agreements with GeNeuron, Inc., for research funding for the development of biologically enhanced devices for treatment of neurovascular disease; provided, as required by the law, Mr. Hankins, Dr. Helm, and Dr. Kallmes file the required annual disclosure statement of personal interests in GeNeuron Therapeutics, Inc., the University files the required annual report concerning the contracts with the Secretary of the Commonwealth, and the Associate Dean for Research vigilantly oversees application of University resources in the best interests of the University and in accordance with policy.